{"filings":[{"id":2106838,"accession_number":"0001297184-26-000045","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-08-06T20:32:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.","GAAP net income $30.3M ($0.67 diluted EPS) vs $31.0M ($0.64) year ago.","Adjusted non-GAAP net income $40.8M ($0.91 diluted EPS) vs $40.9M ($0.85).","CEO cites revenue growth, gross margin expansion, new product launches, and pipeline progress.","Six-month 2026 GAAP net income $36.8M ($0.81) vs $56.3M ($1.15) in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1591319,"accession_number":"0001104659-26-082772","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-07-13T10:01:01+00:00","items":["5.02"],"status":"ready","headline":"Amphastar appoints Anthony Pierce to board, expands to 11 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 directors; Anthony Pierce appointed as Class III director effective July 9, 2026.","Pierce is independent under Nasdaq standards; no committee assignments at this time.","Annual cash retainer of $55,000 (pro-rated); initial equity grant of $300,000 (50% RSUs, 50% options) vests on first anniversary.","Standard indemnification agreement to be entered with Pierce; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1507558,"accession_number":"0001297184-26-000041","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-07-08T00:03:50+00:00","items":["8.01"],"status":"ready","headline":"Amphastar subsidiary IMS receives FDA warning letter for CGMP violations at South El Monte facility","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Warning letter dated July 2, 2026, follows December 2025 FDA inspection of IMS's South El Monte, CA facility.","Cites violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.","FDA does not direct IMS to cease or restrict products from the facility; no further recall required at this time.","IMS must submit initial response within 15 working days and provide a risk assessment and remediation plan.","Company is evaluating impact; additional regulatory or legal action possible if deficiencies are not resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834000,"accession_number":"0001297184-26-000038","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-06-03T20:15:45+00:00","items":["5.07"],"status":"ready","headline":"Amphastar shareholders elect three directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I nominees elected: Gaugh 35.2M for, Peters 23.6M for, Liawatidewi 23.2M for.","Peters and Liawatidewi each received over 11.7M against votes.","Ratification of Ernst & Young as auditor for FY2026 passed 39.2M to 0.7M.","Advisory say-on-pay approved 32.6M for; frequency set at 1 year with 33.8M votes.","All proposals passed with broker non-votes of 4.4M on director and advisory items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91979,"accession_number":"0001297184-26-000031","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues flat at $171.2M vs $170.5M YoY.","GAAP net income $6.4M ($0.14 diluted EPS) vs $25.3M ($0.51) in Q1 2025.","Adjusted non-GAAP net income $19.5M ($0.42 diluted EPS) vs $36.9M ($0.74).","Launched Ipratropium Bromide HFA; signed license for synthetic corticotropin compound."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":171171000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102428,"accession_number":"0001104659-26-027814","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amphastar Board authorizes $50M increase to share buyback program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $50M increase to buyback program on March 12, 2026.","Program has indefinite duration; primary goal is offsetting dilution from equity compensation.","Purchases may be via open market, block trades, Rule 10b5-1 plans, or private transactions.","Timing and number of shares depend on price, regulatory requirements, and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102427,"accession_number":"0001297184-26-000015","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amphastar enters employment agreements with two executives; base salaries $525,800 and $590,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jacob Liawatidewi (EVP of Corp Admin) base salary $525,800, target bonus 55%.","Rong Zhou (Sr EVP of Production) base salary $590,000, target bonus 53%.","Severance: 2x (base + avg bonus) outside CIC; 4x during CIC period.","Full equity acceleration on qualifying termination or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102426,"accession_number":"0001297184-26-000013","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amphastar enters supply agreement with related party Letop, amends contract with Hanxin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supply agreement with Nanjing Letop (Henry Zhang, son of CEO); no minimum purchase, 5-year term.","Contract Research Amendment shifts work from AMP-107 to AMP-105; total cost increased by ~$0.6M.","Both transactions are related-party and approved by Audit Committee; deemed not material.","Payments under supply agreement will be made in Chinese yuan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102425,"accession_number":"0001297184-26-000007","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.","GAAP net income Q4 $24.4M ($0.51 diluted EPS) vs $38.0M ($0.74) in Q4 2024; FY $98.1M ($2.03) vs $159.5M ($3.06).","Adjusted non-GAAP net income Q4 $34.2M ($0.73 diluted EPS) vs $47.2M ($0.92) a year ago.","CEO cites BAQSIMI double-digit growth and FDA approvals of iron sucrose and teriparatide injections as positives.","Three novel peptides and a synthetic corticotropin compound added to pipeline for oncology, ophthalmology, and immunology."],"consensus_eps_estimate":null,"consensus_eps_actual":2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":719887000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102424,"accession_number":"0001297184-26-000002","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.","Upfront payment of $2 million; potential milestones up to $14 million (development) and $75 million (sales).","Royalty payments capped at $7.5 million per year and $60 million total; Hanxin will also pay Amphastar royalties on certain sales.","Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own a majority of Hanxin.","US ACTH market exceeded $684 million in 2024; AMP-110 aims for inflammatory and autoimmune conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118697,"accession_number":"0001297184-25-000062","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $191.8M, flat YoY vs $191.2M.","GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.","Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).","BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.","Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":536782000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118696,"accession_number":"0001297184-25-000058","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.","Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.","10-year term; minimum purchase amounts per contract year; profit sharing above floor price.","Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.","Audit Committee approved the deal; total revenue over 10 years not yet determinable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135210,"accession_number":"0001297184-25-000054","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.","Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.","Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.","Term of three years; all title to RCBs and related IP will belong to Amphastar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135209,"accession_number":"0001558370-25-011134","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amphastar licenses three novel peptides from Anji for up to $453M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.","First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.","Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.","Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.","Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135208,"accession_number":"0001297184-25-000048","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).","Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.","BAQSIMI sales increased 21% YoY, cited as key revenue driver.","Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ."],"consensus_eps_estimate":null,"consensus_eps_actual":1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":344942000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135207,"accession_number":"0001297184-25-000040","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amphastar appoints David Gaugh as Class I director; board size increased to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased authorized directors from 10 to 11 and appointed David Gaugh effective July 18, 2025.","Gaugh will serve until the 2026 annual meeting; no committee assignments at this time.","Initial compensation: $260,000 aggregate grant date fair value, 50% RSUs and 50% stock options, vesting on first anniversary.","Board determined Gaugh is independent under Nasdaq listing standards; no reportable transactions or arrangements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152181,"accession_number":"0001297184-25-000036","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Stockholders approve charter amendments for officer exculpation and forum selection removal at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class III directors: Jack Y. Zhang, Richard Prins, Diane G. Gerst (each with majority support).","Approved charter amendment for officer exculpation under Delaware law (35.5M for, 2.9M against).","Approved removal of forum selection provision from charter (37.4M for, 52k against).","Ratified Ernst & Young as independent auditor for fiscal 2025 (41.5M for).","Bylaws amended to specify Delaware Court of Chancery as exclusive forum for certain internal actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152180,"accession_number":"0001297184-25-000025","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $170.5M, down from $171.8M in Q1 2024.","GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.","Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.","CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.","Company managing resources for efficient operations amid revenue decline."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":170528000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171011,"accession_number":"0001297184-25-000003","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).","FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).","Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).","Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.","CEO cites progress on proprietary pipeline for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":731967000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187987,"accession_number":"0001297184-24-000055","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.","GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.","Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).","Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.","No updated guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":545444000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204490,"accession_number":"0001297184-24-000051","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar subsidiary enters exclusive Primatene MIST distribution deal for Greater China; est. $10M over 10 yrs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Armstrong (Amphastar subsidiary) appoints Genreach as exclusive distributor for Primatene MIST in Mainland China, Taiwan, Hong Kong, Macau; 10-year term.","Estimated total revenue to Amphastar over 10 years is ~$10 million, subject to currency exchange adjustments.","Genreach is responsible for obtaining all regulatory approvals in the region.","Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin, Genreach's parent.","Minimum purchase amounts per contract year; profit sharing based on Genreach's per unit net revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204489,"accession_number":"0001297184-24-000045","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.","GAAP net income $37.9M ($0.73 diluted EPS) vs $26.1M ($0.49) YoY.","Adjusted non-GAAP net income $48.7M ($0.94 diluted EPS) vs $34.8M ($0.65) YoY.","CEO highlighted BAQSIMI as a leading portfolio driver amid transition to branded/biosimilar products."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":354230000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221290,"accession_number":"0001297184-24-000042","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Amphastar board authorizes $50M increase to share buyback program to offset dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$50M increase to buyback program authorized June 3, 2024; program continues indefinitely.","Primary goal is to offset dilution from equity compensation programs.","Purchases may be via open market, block trades, Rule 10b5-1 plans, or negotiated transactions.","Timing and number of shares repurchased depend on price, corporate and regulatory factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221289,"accession_number":"0001297184-24-000033","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.","GAAP net income $43.2M ($0.81 dil EPS) vs $26.0M ($0.50) a year ago.","Adjusted non-GAAP net income $55.3M ($1.04 dil EPS) vs $32.1M ($0.62) YoY.","BAQSIMI revenue grew 22% over Eli Lilly's reported Q1 2023 revenue.","No forward guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":171836000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240844,"accession_number":"0001297184-24-000004","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).","Adjusted non-GAAP Q4 net income $46.9M ($0.88 EPS) vs $37.6M ($0.73 EPS) in Q4 2022.","Full-year net revenue $644.4M (+29% YoY); GAAP net income $137.5M ($2.60 EPS).","Full-year adjusted non-GAAP net income $175.7M ($3.32 EPS) vs $103.2M ($1.97 EPS) in FY2022.","CEO cited strong performance of glucagon, Primatene MIST, BAQSIMI acquisition, and BLA submission for Insulin Aspart."],"consensus_eps_estimate":null,"consensus_eps_actual":2.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":644395000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258350,"accession_number":"0001297184-23-000079","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).","GAAP net income $49.2M ($0.91 diluted EPS) vs $15.9M ($0.30) a year ago.","Adjusted non-GAAP net income $61.9M ($1.15 diluted EPS) vs $20.2M ($0.38).","CEO attributes growth to diabetes portfolio, including BAQSIMI acquisition and generic glucagon.","Nine-month net revenues $466.3M vs $364.0M; GAAP net income $101.4M vs $57.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":466290000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275653,"accession_number":"0001297184-23-000074","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Amphastar issues $345M 2% convertible senior notes due 2029; repays $200M term loan, buys $50M stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$345M aggregate principal (incl. $45M greenshoe exercised) of 2.00% convertible senior notes due 2029, sold via Rule 144A.","Initial conversion price ~$62.96 per share, a 35% premium to $46.64 closing price on Sept 12, 2023.","Net proceeds ~$333.9M; $200M used to repay Wells Fargo credit facility, $50M for stock buyback at $46.64/share.","Notes convertible under certain conditions; company may redeem on/after Sep 21, 2026 if stock >=130% of conversion price.","Remaining proceeds earmarked for general corporate purposes, including BAQSIMI milestone payments and potential M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275651,"accession_number":"0001297184-23-000070","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K/A","filed_at":"2023-08-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.","Q1 2023 revenue $31.4M, up 7.5% YoY from $29.2M; revenue less direct expenses $13.0M vs $9.2M.","Acquisition terms: $500M cash at closing, $125M at one-year anniversary, plus up to $450M in sales milestones.","Net intangible assets of BAQSIMI were $100.3M as of Dec 31, 2022; total assets acquired $187.6M.","Audited abbreviated financial statements cover FY 2021-2022; unaudited for Q1 2023 and 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275652,"accession_number":"0001297184-23-000063","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.","GAAP net income $26.1M ($0.49 diluted EPS) vs $17.3M ($0.33) YoY.","Adjusted non-GAAP net income $34.8M ($0.65 diluted EPS) vs $20.7M ($0.39) YoY.","Completed BAQSIMI acquisition June 30; glucagon, phytonadione, and newer products drove growth.","Six-month: revenue $285.7M, GAAP net income $52.2M ($0.99 EPS), adj. net income $66.9M ($1.27 EPS)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":285734000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293194,"accession_number":"0001297184-23-000057","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01","2.01","2.03","8.01","9.01"],"status":"ready","headline":"Amphastar completes $500M acquisition of BAQSIMI from Lilly; funds with $500M term loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $500M cash at closing; also owes $125M guaranteed payment in one year plus up to $450M contingent milestones.","Entered $500M senior secured term loan (fully drawn) and $200M revolver (undrawn) to finance the deal.","BAQSIMI is a branded intranasal glucagon for severe hypoglycemia; expands Amphastar's diabetes portfolio into 26 countries.","Credit facilities mature June 30, 2028; interest rate initially Term SOFR + 2.25% or base rate + 1.25%.","Lilly will provide manufacturing and transition services for up to 18 months post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293193,"accession_number":"0001297184-23-000053","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amphastar shareholders elect three Class I directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Floyd F. Petersen, Jacob Liawatidewi, and William J. Peters elected as Class I directors to serve until 2026.","Ratification of Ernst & Young as independent auditor for FY2023: 42,097,266 for, 585,099 against.","Advisory vote on executive compensation approved: 37,281,658 for, 1,276,813 against, 4,029,572 broker non-votes.","All proposals passed; meeting held virtually on June 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293192,"accession_number":"0001297184-23-000046","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).","Adjusted non-GAAP net income $32.1M ($0.62 diluted EPS), up from $24.6M ($0.47) YoY.","Key growth drivers: glucagon, Primatene MIST, epinephrine; new launches include regadenoson and intranasal naloxone.","Proposed BAQSIMI acquisition noted as transformative for diabetes portfolio and branded product strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":140022000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293191,"accession_number":"0001558370-23-006469","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Amphastar to buy Lilly's BAQSIMI for $500M cash, $125M guarantee, up to $450M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $500M cash at closing, $125M guaranteed payment at 1-year anniversary, plus up to $450M in sales-based milestones.","BAQSIMI is first and only nasally administered glucagon for severe hypoglycemia; 2022 worldwide sales of $139.3M.","Debt financing: $500M term loan and $150M revolver from Wells Fargo, Capital One, JPMorgan, and others.","Closing expected Q2/Q3 2023, subject to HSR clearance and customary conditions; not subject to financing condition.","Amphastar will use debt and cash on hand; Lilly focuses on pipeline while divesting BAQSIMI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313831,"accession_number":"0001297184-23-000026","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters $0.5M amendment with related party Hanxin for insulin R&D scale-up","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Contract Research Agreement dated July 5, 2022 with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.","Hanxin will perform scale-up manufacturing process development using Recombinant Human Insulin Research Cell Banks (RCBs).","Total cost not to exceed approximately $0.5 million; payments in Chinese yuan adjusted for exchange rates.","Related party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin; Audit Committee approved.","Agreement term matches original contract, currently through July 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313830,"accession_number":"0001297184-23-000012","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).","Full-year 2022 net revenue $499.0M vs $437.8M, GAAP net income $91.4M ($1.74) vs $62.1M ($1.25).","Adjusted non-GAAP Q4 EPS $0.73, full-year $1.97; growth driven by epinephrine, Primatene MIST, and glucagon.","CEO cites strongest quarter and anticipates multiple new product launches in 2023.","No forward guidance provided; financial comparisons are to prior-year periods."],"consensus_eps_estimate":null,"consensus_eps_actual":1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":498987000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313829,"accession_number":"0001297184-23-000007","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Amphastar Pharmaceuticals amends bylaws to update director nomination procedures and adopt forum selection clause","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws on Feb 23, 2023.","New requirement for stockholders to deliver evidence of compliance with Rule 14a-19 no later than five business days before meeting.","Adopted forum selection provision for claims under the Securities Act of 1933.","Updated provisions on directors, committees, officers, and conformed to Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332289,"accession_number":"0001297184-22-000060","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.","Total cost capped at ~$1.5M over 3 years; no minimum purchase obligation for ANP.","Henry Zhang, immediate family of CEO Jack Zhang and Chair Mary Luo, owns majority of Letop; deal was approved by independent Audit Committee members.","ANP retains ownership of all confidential information shared with Letop under the agreement.","Payments in Chinese yuan; price adjustments allowed once per 12 months with 2-month notice and customer consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332288,"accession_number":"0001297184-22-000053","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).","GAAP diluted EPS $0.30 vs $0.59 prior year; adjusted non-GAAP EPS $0.38 vs $0.46.","Nine-month revenues $364.0M vs $316.9M; GAAP net income $57.5M vs $42.4M.","Growth cited from epinephrine, Primatene Mist, and glucagon sales.","No guidance issued; management optimistic about pipeline progress."],"consensus_eps_estimate":null,"consensus_eps_actual":1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":363964000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349753,"accession_number":"0001297184-22-000048","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amphastar expands board to 10, appoints CFO Peters and EVP Liawatidewi as directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 8 to 10, effective August 4, 2022.","William J. Peters (CFO, EVP Finance, Treasurer) appointed as Class I director.","Jacob Liawatidewi (EVP Corporate Administration & Sales/Marketing) appointed as Class I director.","Diane G. Gerst deemed independent; now six of ten directors are independent.","No changes to existing compensatory arrangements for the new directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349752,"accession_number":"0001297184-22-000041","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).","GAAP net income $17.3M ($0.33 diluted EPS) vs $7.8M ($0.16) in Q2 2021.","Adjusted non-GAAP net income $20.7M ($0.39 diluted EPS) vs $10.6M ($0.21) in Q2 2021.","CEO cites strong sales momentum; expects continued growth from ganirelix and vasopressin launch."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":243835000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349751,"accession_number":"0001297184-22-000036","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-07-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar enters $2.2M R&D agreement with related party Hanxin for insulin cell banks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Nanjing Hanxin to develop Recombinant Human Insulin Research Cell Banks (RCBs) and provide exclusive worldwide license.","Total cost capped at ~$2.2M; initial payment ~$0.2M; payments in Chinese yuan.","Related party: CEO Jack Zhang & Chairman Mary Luo family own majority of Hanxin; approved by independent Audit Committee.","Agreement term three years; Amphastar owns all title to RCBs and related IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366805,"accession_number":"0001297184-22-000032","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amphastar stockholders elect three Class III directors, ratify auditor, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Jack Zhang, Richard Prins, Diane Gerst; Zhang received 31,356,354 for, Prins 28,273,064, Gerst 25,594,041.","Ratified Ernst & Young as independent auditor for FY2022; 42,659,628 for, 696,578 against.","Advisory vote on executive compensation approved with 37,248,485 for, 1,247,234 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366804,"accession_number":"0001297184-22-000026","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).","GAAP net income $24.3M ($0.47 diluted EPS) vs $5.0M ($0.10) a year ago.","Adjusted non-GAAP net income $24.6M ($0.47 EPS) vs $13.6M ($0.27) in Q1 2021.","CEO cites strong sales of recent complex product launches; optimistic for continued growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":120368000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366803,"accession_number":"0001297184-22-000021","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Amphastar subsidiary enters contract manufacturing deal with related party Hanxin for Chinese market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANP will manufacture APIs and finished products on cost-plus basis for Hanxin, which will file for Chinese marketing authorizations.","Hanxin, majority-owned by Drs. Zhang, Luo and family, is a related party; deal approved by independent disinterested directors.","Hanxin commits to minimum purchase quantities under the agreement dated April 19, 2022; material terms to be filed with Q2 2022 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386195,"accession_number":"0001297184-22-000003","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.","Full-year net revenues $437.8M vs $349.8M in 2020; GAAP net income $62.1M vs $1.4M.","Adjusted non-GAAP diluted EPS $0.42 for Q4 and $1.37 for full year.","CEO cites continued growth of higher-margin products and expects pipeline milestones in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404114,"accession_number":"0001297184-21-000062","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.","GAAP net income $29.5M ($0.59 diluted EPS) vs $3.9M ($0.08) a year ago.","Adjusted non-GAAP net income $23.0M ($0.46 EPS) vs $7.6M ($0.15).","Growth driven by glucagon, Primatene Mist, epinephrine; CEO expects pipeline approvals in 2022.","Nine-month net revenues $316.9M, up 25% YoY; GAAP net income $42.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":316881000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423091,"accession_number":"0001297184-21-000057","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2021-08-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amphastar director David Maris resigns effective immediately; no disagreement with company","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Maris resigned from the Board on August 19, 2021, effective immediately.","Resignation is not the result of any disagreement with company operations, policies, or practices.","Company expressed appreciation for Maris's service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423090,"accession_number":"0001297184-21-000054","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2021-08-20T23:59:59+00:00","items":["1.01","2.01","5.02"],"status":"ready","headline":"Amphastar to acquire remaining ~15% of Nanjing subsidiary for $22.5M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Signed SPA for ~15% stake in Amphastar Nanjing Pharmaceuticals (ANP) from QQ for ~$22.5M.","Deal subject to regulatory approval; after closing, Amphastar will own 100% of ANP.","QQ is controlled by COO/Chairman Mary Luo, CEO Jack Zhang, and family members.","Proceeds: APCL $18.96M, Bill Zhang $3.37M, Chongqing Zhang $0.21M.","Transaction price based on independent valuation and deemed fair by disinterested directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423089,"accession_number":"0001297184-21-000051","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Richard Koo to retire from Amphastar Board effective Sept 30, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Koo announced retirement from Board effective September 30, 2021; not due to any disagreement.","Koo served 18 years on the Board; departure planned and amicable.","No successor or additional board changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423088,"accession_number":"0001297184-21-000046","cik":1297184,"company_name":"Amphastar Pharmaceuticals, Inc.","ticker":"AMPH","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amphastar Q2 revenue $101.7M, GAAP EPS $0.16, adjusted EPS $0.21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $101.7M, up 18.5% YoY from $85.8M in Q2 2020.","GAAP net income $7.8M ($0.16 diluted EPS) vs loss of $0.00 EPS a year ago.","Adjusted non-GAAP net income $10.6M ($0.21 diluted EPS) vs $0.16 prior year.","Strong sales of glucagon, Primatene Mist, and epinephrine products drove growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":204683000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":853638917.009424,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-09T23:59:59+00:00|423088"}